BTG Specialty Pharmaceuticals

BTG Specialty Pharmaceuticals Advances Global Regulatory Program for Glucarpidase, Sold as Voraxaze in US

WEST CONSHOHOCKEN, PA — BTG Specialty Pharmaceuticals announced that Ohara Pharmaceutical Co., Ltd. recently obtained marketing authorization for glucarpidase from Japan’s Ministry of Health, Labour and Welfare as a therapeutic …

BTG Specialty Pharmaceuticals Advances Global Regulatory Program for Glucarpidase, Sold as Voraxaze in US Read More

Idera Pharmaceuticals

Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab

EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory …

Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab Read More